MetLife Investment Management
LRMR icon

MetLife Investment Management’s Larimar Therapeutics LRMR Stock Holding History

MetLife Investment Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Buy
39,798
+13,130
+49% +$52.1K ﹤0.01% 2698
2026
Q1 		$120K Buy
26,668
+13,071
+96% +$52.2K ﹤0.01% 2454
2025
Q4 		$51.8K Sell
13,597
-12,110
-47% -$47.1K ﹤0.01% 2724
2025
Q3 		$83K Sell
25,707
-652
-2% -$2.44K ﹤0.01% 2725
2025
Q2 		$76.2K Buy
+26,359
New +$61K ﹤0.01% 2652
2025
Q1 		– Sell
-18,428
Closed -$71.3K – 2807
2024
Q4 		$71.3K Sell
18,428
-6,377
-26% -$42.1K ﹤0.01% 2706
2024
Q3 		$162K Hold
24,805
– – ﹤0.01% 2392
2024
Q2 		$180K Buy
24,805
+10,882
+78% +$83.3K ﹤0.01% 2318
2024
Q1 		$106K Buy
+13,923
New +$108K ﹤0.01% 2507
2018
Q4 		– Sell
-1,279
Closed -$179K – 2584
2018
Q3 		$179K Buy
+1,279
New +$155K ﹤0.01% 2145

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

MetLife Investment Management's LRMR Position: Q2 2026 in Review

MetLife Investment Management increased its Larimar Therapeutics (LRMR) stake by 49% in Q2 2026, buying an estimated $52.1K and bringing the position to 39,798 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #2698.

MetLife Investment Management first reported a position in LRMR in Q3 2018 and has held it in 10 quarters since. The position peaked at $180K in Q2 2024. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • MetLife Investment Management held 39,798 shares of Larimar Therapeutics worth $121K as of Q2 2026.
  • MetLife Investment Management bought 13,130 Larimar Therapeutics shares in Q2 2026, an estimated $52.1K.
  • Larimar Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2698 holding.
  • MetLife Investment Management first reported a position in Larimar Therapeutics in Q3 2018 and has held it in 10 quarters since.
  • MetLife Investment Management's Larimar Therapeutics position peaked at $180K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.